|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In ER/PR/HER2(-) patients the OPN levels in breast tumors were significantly higher than in corresponding normal breast tissue samples, whereas in the single ER/PR/HER2(+) patient the OPN concentration in tumor samples was lower than in normal breast tissue sample.
|
31374364 |
2019 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Similarly, after intravenous administration of the osteopontin-750 probe, it accumulated preferentially in the subcutaneous breast tumor in nude mice (557 MSOT a.u. compared to untargeted organs such as kidney (53.7 MSOT a.u.) and liver (32.1 MSOT a.u.).
|
30260254 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Elevated mRNA expression of SPP1 gene was revealed in breast tumors (2-7-fold) that correlated with SPP1 antigen immunoreactivity in autologous patients' sera.
|
27775439 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ADAM9 silencing in MDA-MB-231 cells had no influence in expression of several genes related to the metastatic process such as ADAM10, ADAM12, ADAM17, cMYC, MMP9, VEGF-A, VEGF-C, osteopontin and collagen XVII.
|
27554339 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
OPN also regulates hypoxia-inducible factor-1α-dependent VEGF expression leading to breast tumor growth and angiogenesis in response to hypoxia.
|
24899149 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
|
23728336 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1.
|
23416968 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Promotion of metastasis in response to miR-224 downregulation was associated with derepression of the stroma-associated RKIP target genes, CXCR4, MMP1, and OPN, which are involved in breast tumor metastasis to the bone.
|
22809510 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway.
|
22804248 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester).
|
22531848 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus, we demonstrate for the first time a role for Merlin in impeding breast malignancy, identify a novel mechanism for the loss of Merlin protein in breast cancer, and have developed a discriminatory model using Merlin and OPN expression in breast tumor tissues.
|
21965655 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study.
|
18949741 |
2009 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study.
|
18949741 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice.
|
18266970 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation.
|
17227585 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The role of osteopontin in tumor progression and metastasis in breast cancer.
|
17548669 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management.
|
17721886 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Thus, in addition to the widely reported roles of OPN in late stages of tumor progression, these results provide functional evidence that OPN contributes to breast tumor growth as well.
|
16830223 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, in addition to the widely reported roles of OPN in late stages of tumor progression, these results provide functional evidence that OPN contributes to breast tumor growth as well.
|
16830223 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin.
|
14517343 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The mRNA level of OPN, a bone matrix protein associated with enhanced malignancy, increased in non-invasive, invasive, and liver and bone metastatic breast tumor tissue compared to normal breast tissue.
|
12206515 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis.
|
11801541 |
2002 |